Hims & Hers Health, Inc. (HIMS)
Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down
HIMS posts a wider-than-expected loss and weaker gross margin in second-quarter 2026 despite strong revenue growth and a raised full-year outlook.
Hims & Hers Q2 revenue beat offset by wider-than-expected loss
Hims & Hers Health (NYSE:HIMS) delivered mixed second-quarter results, with revenue beating Wall Street expectations while its quarterly loss came in wider than analysts had forecast as the company incurred restructuring charges tied to its shift toward branded GLP-1 weight-loss options. Revenue for the quarter ended June 30 rose 38% year over year to $753.2 million, topping the roughly $699 million analysts had expected.
HIMS Q2 Earnings Call Focuses on AI and Global Expansion
Hims & Hers raises its 2026 revenue outlook as AI boosts engagement, specialty care expands and Eucalyptus extends its international reach despite margin pressure.
Hims & Hers Health Slides on Wider-Than-Expected Q2 Loss
Hims & Hers Health (NYSE:HIMS) shares were last seen down 7% to trade at $29.54.
Hims & Hers shares slide as costly weight-loss push squeezes margins
Hims & Hers Health's shares fell nearly 7% in premarket trading on Tuesday, as concerns over shrinking profit margins overshadowed strong subscriber growth and a raised annual revenue forecast.
Hims & Hers stock drops 7% despite higher guidance: what went wrong?
Shares of Hims & Hers Health fell more than 7% in premarket trading on Tuesday after the telehealth company reported a wider-than-expected second-quarter loss, as investments in branded GLP-1 weight-loss treatments and international expansion weighed on profitability. The company reported a net loss of 37 cents per share for the quarter, compared with analysts' expectations for a loss of 1 cent per share, according to LSEG data.
Hims & Hers Health Q2 Earnings Call Highlights
Hims & Hers Health NYSE: HIMS reported second-quarter 2026 revenue of more than $753 million, up nearly 40% from a year earlier, as the telehealth company added 300,000 net new subscribers and ended the period with nearly 3 million subscribers globally.
Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates
Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.17 per share a year ago.
Can Weight-Loss Momentum Lift Hims & Hers Stock Before Q2 Earnings?
HIMS' second-quarter 2026 results are likely to benefit from weight-loss demand and global expansion even as margin pressures and higher spending linger.
Hims & Hers Health, Inc. (HIMS) Declines More Than Market: Some Information for Investors
Hims & Hers Health, Inc. (HIMS) closed at $31.65 in the latest trading session, marking a -1.59% move from the prior day.
Hims & Hers Health: Still An Undervalued Company With Tremendous Upside
Hims & Hers Health remains deeply undervalued despite a 578% stock gain since 2022, with fundamentals vastly improved. HIMS is projected to reach $3.5B revenue in 2026 and potentially $9B by 2030, driven by GLP-1 adoption, peptides, and international expansion. Insider and institutional ownership have increased, margins remain robust at 73%, and subscriber growth is accelerating, especially via the Novo partnership.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.32, indicating a -3.04% shift from the previous trading day.
